My Portfolio
+
LINK YOUR PORTFOLIO

Atara Biotherapeutics Inc ATRA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 06/02/26 EDT
9.63quote price arrow down-0.27 (-2.73%)
Volume
103,528
52 week range
3.92 - 19.15
Loading...
  • Open10.03
  • Day High10.23
  • Day Low9.35
  • Prev Close9.63
  • 52 Week High19.15
  • 52 Week High Date01/05/26
  • 52 Week Low3.92
  • 52 Week Low Date02/23/26

Latest On Atara Biotherapeutics Inc

 

Key Stats

  • Market Cap86.768M
  • Shares Out9.01M
  • 10 Day Average Volume0.13M
  • Dividend-
  • Dividend Yield-
  • Beta0.11

Latest On Atara Biotherapeutics Inc

 

KEY STATS

  • Open10.03
  • Day High10.23
  • Day Low9.35
  • Prev Close9.63
  • 52 Week High19.15
  • 52 Week High Date01/05/26
  • 52 Week Low3.92
  • 52 Week Low Date02/23/26
  • Market Cap86.768M
  • Shares Out9.01M
  • 10 Day Average Volume0.13M
  • Dividend-
  • Dividend Yield-
  • Beta0.11

RATIOS/PROFITABILITY

  • EPS (TTM)-0.86
  • P/E (TTM)-11.19
  • Fwd P/E (NTM)-9.08
  • EBITDA (TTM)-3.112M
  • ROE (TTM)-2,014.86%
  • Revenue (TTM)23.139M
  • Gross Margin (TTM)96.12%
  • Net Margin (TTM)-40.91%
  • Debt To Equity (MRQ)-111.15%

EVENTS

  • Earnings Date08/10/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant...
Gregory Ciongoli
Non-Executive Chairman of the Board
Anhco Nguyen Ph.D.
President, Chief Executive Officer, Director
Address
1280 Rancho Conejo Blvd
Thousand Oaks, CA
91320
United States